Article

World's Largest MSK Study Shows Hinge Health's Digital Solution Directly Reduces Back and Joint Pain

New large-scale study: Hinge Health exercise therapy and coaching reduced musculoskeletal pain by 69% and improved mental health and surgery outcomes in 10,000+ participant longitudinal study.

San Francisco, CA (May 11, 2020)—As more patients and employers turn to digital health solutions during COVID-19, researchers at Stanford, UCSF, and Vanderbilt published on Monday the first large-scale study proving the effectiveness of digital health in reducing chronic back & joint pain. The study demonstrates that each Hinge Health remote exercise therapy and coaching session has a direct correlation to pain reduction. In the world’s largest digital musculoskeletal (MSK) longitudinal study (N = 10,264), each Hinge Health participant had an average pain reduction of 69%, reduced depression and anxiety 58%, increased productivity 61% and decreased surgery likelihood 67%. Hinge Health’s unique 1-on-1 coaching model helped drive the industry’s highest 12-week completion rate, 73%, with each participant completing an average of 35 exercise therapy sessions.

Hinge Health Chief Medical Officer, Dr. Jeffrey Krauss said, “Hinge Health is the first digital MSK company to publish a peer-reviewed large-scale study. Hinge Health’s best-in-class adherence and elective surgery avoidance rates validates why we’ve made the market-leading investment to have both physical therapists and 10x more health coaches support participants with chronic MSK pain.”

Read the full press release here.

Related Videos
Jonathan Eisengart
Robin Glasco, Spencer Stuart
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Nadine Barrett, PhD
Neil Goldfarb, GPBCH
Dr Bonnie Qin
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo